Genetic variation associated with euphorigenic effects of d-amphetamine is associated with diminished risk for schizophrenia and attention deficit hyperactivity disorder

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 16, 2014, Pages 5968-5973

  Hart, Amy B ^a   Gamazon, Eric R ^a   Engelhardt, Barbara E ^b   Sklar, Pamela ^c   Kähler, Anna K ^d   Hultman, Christina M ^d   Sullivan, Patrick F ^e   Neale, Benjamin M ^f   Faraone, Stephen V ^g   De Wit, Harriet ^a   Cox, Nancy J ^a   Palmer, Abraham A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Bipolar disorder; Dopamine hypothesis; Endophenotype; GWAS; Stimulant

Indexed keywords

DEXAMPHETAMINE;

ALLELE; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CONTROLLED STUDY; EUPHORIA; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

BIPOLAR DISORDER; DOPAMINE HYPOTHESIS; ENDOPHENOTYPE; GWAS; STIMULANT;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIPOLAR DISORDER; DEXTROAMPHETAMINE; EUPHORIA; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTECTIVE AGENTS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SCHIZOPHRENIA;

EID: 84899071798     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1318810111     Document Type: Article

References (43)

1. Nicolae DL, et al. (2010) Trait-associated SNPs are more likely to be eQTLs: Annotation to enhance discovery from GWAS. PLoS Genet 6(4):e1000888.
2. Davis LK, et al. (2012) Loci nominally associated with autism from genome-wide analysis show enrichment of brain expression quantitative trait loci but not lymphoblastoid cell line expression quantitative trait loci. Mol Autism 3(1):3.
3. Gamazon ER, Huang RS, Cox NJ, Dolan ME (2010) Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci USA 107(20):9287-9292.
4. Gamazon ER, et al. (2013) Enrichment of cis-regulatory gene expression SNPs and methylation quantitative trait loci among bipolar disorder susceptibility variants. Mol Psychiatry 18(3):340-346.
5. Zhong H, Yang X, Kaplan LM, Molony C, Schadt EE (2010) Integrating pathway analysis and genetics of gene expression for genome-wide association studies. Am J Hum Genet 86(4):581-591.
6. Smoller JW, et al.; Cross-Disorder Group of the Psychiatric Genomics Consortium; Genetic Risk Outcome of Psychosis (GROUP) Consortium (2013) Identification of risk loci with shared effects on five major psychiatric disorders: A genome-wide analysis. Lancet 381(9875):1371-1379.
7. Hart AB, et al. (2012) Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13). PLoS ONE 7(8):e42646.
8. Kuczenski R, Segal DS (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: Comparison with amphetamine. J Neurochem 68(5):2032-2037. (Pubitemid 27176139)
9. Franke A, et al. (2010) Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 42(12):1118-1125.
10. Ripke S, et al.; Multicenter Genetic Studies of Schizophrenia Consortium; Psychosis Endophenotypes International Consortium; Wellcome Trust Case Control Consortium 2 (2013) Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 45(10):1150-1159.
11. Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 20(1963):140-144.
12. Van Rossum JM (1966) The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 160(2):492-444.
13. Abi-Dargham A (2004) Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 7(Suppl 1):S1-S5.
14. Kendler KS, Schaffner KF (2011) The dopamine hypothesis of schizophrenia: An historical and philosophical analysis. Philos Psychiatry Psychol 18(1):41-63.
15. Peroutka SJ, Synder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137(12):1518-1522. (Pubitemid 11196805)
16. Snyder SH (1973) Amphetamine psychosis: A "model" schizophrenia mediated by catecholamines. Am J Psychiatry 130(1):61-67.
17. Abi-Dargham A, et al. (1998) Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am J Psychiatry 155(6):761-767. (Pubitemid 28252654)
18. Laruelle M, et al. (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93(17):9235-9240.
19. Gonon F (2009) The dopaminergic hypothesis of attention-deficit/ hyperactivity disorder needs re-examining. Trends Neurosci 32(1):2-8.
20. Wender PH (1971) Minimal Brain Dysfunction in Children (Wiley Interscience, New York).
21. Warikoo N, Faraone SV (2013) Background, clinical features and treatment of attention deficit hyperactivity disorder in children. Expert Opin Pharmacother 14(14):1885-1906.
22. Biederman J (2003) Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: Findings from a longitudinal follow-up of youths with and without ADHD. J Clin Psychiatry 64(Suppl 11):3-8.
23. Groenman AP, et al. (2013) Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder. Br J Psychiatry 203(2):112-119.
24. Keshavan MS, Sujata M, Mehra A, Montrose DM, Sweeney JA (2003) Psychosis proneness and ADHD in young relatives of schizophrenia patients. Schizophr Res 59(1):85-92. (Pubitemid 35284498)
25. Larsson H, et al. (2013) Risk of bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity disorder. Br J Psychiatry 203(2):103-106.
26. Hamshere ML, et al. (2013) Shared polygenic contribution between childhood attention-deficit hyperactivity disorder and adult schizophrenia. Br J Psychiatry 203(2):107-111.
27. Lee SH, et al.; Cross-Disorder Group of the Psychiatric Genomics Consortium; International Inflammatory Bowel Disease Genetics Consortium (IIBDGC) (2013) Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 45(9):984-994.
28. Faraone SV, Biederman J, Wozniak J (2012) Examining the comorbidity between attention deficit hyperactivity disorder and bipolar I disorder: A meta-analysis of family genetic studies. Am J Psychiatry 169(12):1256-1266.
29. Kelsoe JR, Niculescu AB, 3rd (2002) Finding genes for bipolar disorder in the functional genomics era: From convergent functional genomics to phenomics and back. CNS Spectr 7(3):215-216, 223-226.
30. Ray LA, Hutchison KE (2004) A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 28(12):1789-1795. (Pubitemid 39665194)
31. Ramchandani VA, et al. (2011) A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry 16(8):809-817.
32. Setiawan E, et al. (2011) The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: Influence of gender and genotype. Alcohol Clin Exp Res 35(6):1134-1141.
33. King AC, de Wit H, McNamara PJ, Cao D (2011) Rewarding, stimulant, and sedative alcohol responses and relationship to future binge drinking. Arch Gen Psychiatry 68(4):389-399.
34. de Wit H, Phillips TJ (2012) Do initial responses to drugs predict future use or abuse? Neurosci Biobehav Rev 36(6):1565-1576.
35. Cichon S, et al.; Psychiatric GWAS Consortium Coordinating Committee (2009) Genomewide association studies: History, rationale, and prospects for psychiatric disorders. Am J Psychiatry 166(5):540-556.
36. Johanson CE, Uhlenhuth EH (1980) Drug preference and mood in humans: Diazepam. Psychopharmacology (Berl) 71(3):269-273. (Pubitemid 11194003)
37. Chait LD, Fischman MW, Schuster CR (1985) 'Hangover' effects the morning after marijuana smoking. Drug Alcohol Depend 15(3):229-238. (Pubitemid 15031761)
38. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12(2):245-258.
39. Engelhardt BE, Stephens M (2010) Analysis of population structure: A unifying framework and novel methods based on sparse factor analysis. PLoS Genet 6(9):e1001117.
40. Altshuler DM, et al.; International HapMap 3 Consortium (2010) Integrating common and rare genetic variation in diverse human populations. Nature 467(7311):52-58.
41. Abecasis GR, et al.; 1000 Genomes Project Consortium (2010) A map of human genome variation from population-scale sequencing. Nature 467(7319):1061-1073.
42. Patterson N, Price AL, Reich D (2006) Population structure and eigenanalysis. PLoS Genet 2(12):e190.
43. Purcell S, et al. (2007) PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81(3):559-575. (Pubitemid 47330214)